BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 36042208)

  • 1. Inhibitory effect of the novel tyrosine kinase inhibitor DCC-2036 on triple-negative breast cancer stem cells through AXL-KLF5 positive feedback loop.
    Shen Y; Zhu Q; Xiao M; Yin L; Feng W; Feng J; He J; Li P; Chen X; Ding W; Zhong J; Zeng Z; Xie Z; Liu J; Zu X
    Cell Death Dis; 2022 Aug; 13(8):749. PubMed ID: 36042208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic activity of DCC-2036, a novel tyrosine kinase inhibitor, against triple-negative breast cancer patient-derived xenografts by targeting AXL/MET.
    Shen Y; Zhang W; Liu J; He J; Cao R; Chen X; Peng X; Xu H; Zhao Q; Zhong J; Ding W; Lei X; Jiang Y; Zu X
    Int J Cancer; 2019 Feb; 144(3):651-664. PubMed ID: 30289981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tyrosine kinase SRC-induced YAP1-KLF5 module regulates cancer stemness and metastasis in triple-negative breast cancer.
    Zou H; Luo J; Guo Y; Tong T; Liu Y; Chen Y; Xiao Y; Ye L; Zhu C; Deng L; Wang B; Pan Y; Li P
    Cell Mol Life Sci; 2023 Jan; 80(2):41. PubMed ID: 36633714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein kinase C α is involved in the regulation of AXL receptor tyrosine kinase expression in triple-negative breast cancer cells.
    Yue CH; Liu LC; Kao ES; Lin H; Hsu LS; Hsu CW; Lin YY; Lin YS; Liu JY; Lee CJ
    Mol Med Rep; 2016 Aug; 14(2):1636-42. PubMed ID: 27357025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The AXL-PYK2-PKCα axis as a nexus of stemness circuits in TNBC.
    Khera L; Vinik Y; Maina F; Lev S
    Life Sci Alliance; 2021 Jun; 4(6):. PubMed ID: 33785524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-217 inhibits triple-negative breast cancer cell growth, migration, and invasion through targeting KLF5.
    Zhou W; Song F; Wu Q; Liu R; Wang L; Liu C; Peng Y; Mao S; Feng J; Chen C
    PLoS One; 2017; 12(4):e0176395. PubMed ID: 28437471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. UCHL1 contributes to insensitivity to endocrine therapy in triple-negative breast cancer by deubiquitinating and stabilizing KLF5.
    Li J; Liang Y; Zhou S; Chen J; Wu C
    Breast Cancer Res; 2024 Mar; 26(1):44. PubMed ID: 38468288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic Landscape of AXL Receptor Kinase in Triple-Negative Breast Cancer.
    Ozyurt R; Ozpolat B
    Mol Cancer Ther; 2023 Jul; 22(7):818-832. PubMed ID: 37028809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DANCR Induces Cisplatin Resistance of Triple-Negative Breast Cancer by KLF5/p27 Signaling.
    Su A; Yao K; Zhang H; Wang Y; Zhang H; Tang J
    Am J Pathol; 2023 Mar; 193(3):248-258. PubMed ID: 36509121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GSK3β regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer.
    Vijay GV; Zhao N; Den Hollander P; Toneff MJ; Joseph R; Pietila M; Taube JH; Sarkar TR; Ramirez-Pena E; Werden SJ; Shariati M; Gao R; Sobieski M; Stephan CC; Sphyris N; Miura N; Davies P; Chang JT; Soundararajan R; Rosen JM; Mani SA
    Breast Cancer Res; 2019 Mar; 21(1):37. PubMed ID: 30845991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mifepristone Suppresses Basal Triple-Negative Breast Cancer Stem Cells by Down-regulating KLF5 Expression.
    Liu R; Shi P; Nie Z; Liang H; Zhou Z; Chen W; Chen H; Dong C; Yang R; Liu S; Chen C
    Theranostics; 2016; 6(4):533-44. PubMed ID: 26941846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined inhibition of AXL, Lyn and p130Cas kinases block migration of triple negative breast cancer cells.
    Pénzes K; Baumann C; Szabadkai I; Orfi L; Kéri G; Ullrich A; Torka R
    Cancer Biol Ther; 2014; 15(11):1571-82. PubMed ID: 25482942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of an AXL kinase inhibitor in triple-negative breast cancer by structure-based virtual screening and bioactivity test.
    Li P; Niu Y; Li S; Zu X; Xiao M; Yin L; Feng J; He J; Shen Y
    Chem Biol Drug Des; 2022 Feb; 99(2):222-232. PubMed ID: 34679238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metformin suppresses triple-negative breast cancer stem cells by targeting KLF5 for degradation.
    Shi P; Liu W; Tala ; Wang H; Li F; Zhang H; Wu Y; Kong Y; Zhou Z; Wang C; Chen W; Liu R; Chen C
    Cell Discov; 2017; 3():17010. PubMed ID: 28480051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mifepristone Derivative FZU-00,003 Suppresses Triple-negative Breast Cancer Cell Growth partially via miR-153-KLF5 axis.
    Liu R; Chen H; Zhao P; Chen CH; Liang H; Yang C; Zhou Z; Zhi X; Liu S; Chen C
    Int J Biol Sci; 2020; 16(4):611-619. PubMed ID: 32025209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KLF4 defines the efficacy of the epidermal growth factor receptor inhibitor, erlotinib, in triple-negative breast cancer cells by repressing the EGFR gene.
    Roberts MS; Anstine LJ; Finke VS; Bryson BL; Webb BM; Weber-Bonk KL; Seachrist DD; Majmudar PR; Keri RA
    Breast Cancer Res; 2020 Jun; 22(1):66. PubMed ID: 32552913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl.
    Dine JL; O'Sullivan CC; Voeller D; Greer YE; Chavez KJ; Conway CM; Sinclair S; Stone B; Amiri-Kordestani L; Merchant AS; Hewitt SM; Steinberg SM; Swain SM; Lipkowitz S
    Breast Cancer Res Treat; 2016 Jan; 155(2):235-51. PubMed ID: 26759246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Global phosphotyrosine survey in triple-negative breast cancer reveals activation of multiple tyrosine kinase signaling pathways.
    Wu X; Zahari MS; Ma B; Liu R; Renuse S; Sahasrabuddhe NA; Chen L; Chaerkady R; Kim MS; Zhong J; Jelinek C; Barbhuiya MA; Leal-Rojas P; Yang Y; Kashyap MK; Marimuthu A; Ling M; Fackler MJ; Merino V; Zhang Z; Zahnow CA; Gabrielson E; Stearns V; Roa JC; Sukumar S; Gill PS; Pandey A
    Oncotarget; 2015 Oct; 6(30):29143-60. PubMed ID: 26356563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. G protein-coupled KISS1 receptor is overexpressed in triple negative breast cancer and promotes drug resistance.
    Blake A; Dragan M; Tirona RG; Hardy DB; Brackstone M; Tuck AB; Babwah AV; Bhattacharya M
    Sci Rep; 2017 Apr; 7():46525. PubMed ID: 28422142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mithramycin A suppresses basal triple-negative breast cancer cell survival partially via down-regulating Krüppel-like factor 5 transcription by Sp1.
    Liu R; Zhi X; Zhou Z; Zhang H; Yang R; Zou T; Chen C
    Sci Rep; 2018 Jan; 8(1):1138. PubMed ID: 29348684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.